ArriVent BioPharma Inc AVBP Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$13.66 up $1.43, 11.69% at close Nov 6
Last close · Previous close $12.23
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$3.62Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$13.66up $1.43, 11.69%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$12.23Nov 5
- Volume1.10MNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.63MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $11.36 to $35.83; now $13.66
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
AVBP trailed the S&P 500 in all 4 periods.
| Period | AVBP and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | AVBP: down 9.5% S&P 500: down 5.6% | AVBP trailed the S&P 500 by 3.9 percentage points Trailed |
| 3M | AVBP: down 55.9% S&P 500: down 4.1% | AVBP trailed the S&P 500 by 51.8 percentage points Trailed |
| YTD | AVBP: down 32.1% S&P 500: up 8.7% | AVBP trailed the S&P 500 by 40.8 percentage points Trailed |
| 1Y | AVBP: down 25.7% S&P 500: up 10.9% | AVBP trailed the S&P 500 by 36.6 percentage points Trailed |
$10,000 invested in AVBP a year ago (Nov 6, 2025) would be worth about $7,428 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $11,088.
AVBP trailed the S&P 500 in all 4 periods.
| Period | AVBP and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | AVBP: down 9.5% S&P 500: down 5.6% | AVBP trailed the S&P 500 by 3.9 percentage points Trailed |
| 3M | AVBP: down 55.9% S&P 500: down 4.3% | AVBP trailed the S&P 500 by 51.6 percentage points Trailed |
| YTD | AVBP: down 32.1% S&P 500: up 7.8% | AVBP trailed the S&P 500 by 39.9 percentage points Trailed |
| 1Y | AVBP: down 25.7% S&P 500: up 9.7% | AVBP trailed the S&P 500 by 35.4 percentage points Trailed |
$10,000 invested in AVBP a year ago (Nov 6, 2025) would be worth about $7,428 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,969.
All-time high
$35.63
Closing high on . Now 61.7% below that record.
Split-adjusted daily closes since Jan 26, 2024.
Stock splits
AVBP hasn’t split since its price history begins in 2024.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$163.74M
- Diluted EPS
- −$3.62
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$20.56M | −$0.61 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$20.63M | −$0.61 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$64.39M | −$1.90 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$31.40M | −$0.90 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$34.98M | −$0.83 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$35.54M | −$0.78 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$43.32M | −$0.96 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$49.89M | −$1.05 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY22 (Dec 31, 2022) | $0.00 | −$36.91M | −$28.90 |
| FY23 (Dec 31, 2023) | $0.00 | −$69.33M | −$32.38 |
| FY24 (Dec 31, 2024) | $0.00 | −$80.49M | −$2.56 |
| FY25 (Dec 31, 2025) | $0.00 | −$166.31M | −$4.32 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$147.93MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$147.93MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $261.87MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $373.12MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$351.00KAs of Jun 30, 2026
- Net cash$372.77MAs of Jun 30, 2026
- 14.16As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −50.3%Last 12 months
Over the last 12 months, ArriVent BioPharma lost money: its net loss was 50.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −46.7%Last 12 months
Over the last 12 months, ArriVent BioPharma’s net loss was 46.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About ArriVent BioPharma Inc
ArriVent BioPharma Inc
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Pennsylvania, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
AVBP news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
AVBP stock FAQ
What is AVBP stock’s price today?
ArriVent BioPharma (AVBP) traded at $13.66 at the close on , up $1.43 (11.69%) from the previous close of $12.23. Over the past 52 weeks it has traded between $11.36 and $35.83.
What is AVBP’s P/E ratio?
AVBP’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$3.62).
What are AVBP’s earnings per share?
AVBP’s diluted earnings per share were −$3.62 over the four quarters to , compared with −$4.02 in the twelve months before. The latest quarter (Q2 FY26) brought −$1.05 per share, against −$0.90 a year earlier (how EPS works).
Does AVBP pay a dividend?
ArriVent BioPharma hasn’t paid a dividend in the last twelve months.
What is AVBP’s 52-week high and low?
Over the past 52 weeks AVBP has traded as low as $11.36 and as high as $35.83. At $13.66 at the close on , it is 61.9% below that high and 20.2% above the low.
What is AVBP’s all-time high?
AVBP’s highest closing price was $35.63 on , adjusted for stock splits. At $13.66 at the close on , it is 61.7% below that record.
Has AVBP stock ever split?
No. AVBP hasn’t split since its price history begins in 2024.
How has AVBP stock performed?
Including dividends and measured to the close on , AVBP has returned −32.1% so far this year and −25.7% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.7% and +10.9%. Past performance doesn’t predict future returns.
What sector and industry is ArriVent BioPharma in?
ArriVent BioPharma is in the Healthcare sector and the Biotechnology industry, and is headquartered in Pennsylvania, USA.
What exchange does AVBP trade on?
ArriVent BioPharma trades on the Nasdaq under the ticker symbol AVBP. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.